TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of “Hold” from Analysts

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) have been given an average rating of “Hold” by the six research firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $6.00.

TCRX has been the subject of several research reports. Wall Street Zen cut shares of TScan Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of TScan Therapeutics in a research report on Tuesday, April 21st. Wedbush reaffirmed an “outperform” rating and set a $5.00 price objective on shares of TScan Therapeutics in a research report on Tuesday. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price objective on shares of TScan Therapeutics in a research report on Tuesday.

TScan Therapeutics Stock Performance

Shares of TCRX opened at $0.92 on Wednesday. TScan Therapeutics has a one year low of $0.85 and a one year high of $2.57. The company has a 50-day moving average of $1.07 and a two-hundred day moving average of $1.06. The stock has a market cap of $60.19 million, a price-to-earnings ratio of -0.96 and a beta of 1.03. The company has a debt-to-equity ratio of 0.34, a current ratio of 6.65 and a quick ratio of 6.65.

TScan Therapeutics (NASDAQ:TCRX) last announced its earnings results on Wednesday, May 6th. The company reported ($0.22) EPS for the quarter, hitting the consensus estimate of ($0.22). TScan Therapeutics had a negative net margin of 1,360.61% and a negative return on equity of 91.94%. The company had revenue of $0.98 million during the quarter, compared to analysts’ expectations of $2.50 million. On average, equities research analysts expect that TScan Therapeutics will post -1.11 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Boothbay Fund Management LLC lifted its stake in TScan Therapeutics by 50.0% in the second quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock valued at $35,000 after acquiring an additional 8,121 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in TScan Therapeutics by 6.0% in the first quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company’s stock valued at $235,000 after acquiring an additional 9,676 shares during the last quarter. Bank of America Corp DE lifted its stake in TScan Therapeutics by 48.7% in the first quarter. Bank of America Corp DE now owns 57,529 shares of the company’s stock valued at $58,000 after acquiring an additional 18,829 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in TScan Therapeutics by 8.5% in the second quarter. JPMorgan Chase & Co. now owns 287,743 shares of the company’s stock valued at $417,000 after acquiring an additional 22,642 shares during the last quarter. Finally, Panagora Asset Management Inc. acquired a new stake in TScan Therapeutics in the fourth quarter valued at approximately $25,000. 82.83% of the stock is owned by hedge funds and other institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.